Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.

Mirza S, Rakha EA, Alshareeda A, Mohibi S, Zhao X, Katafiasz BJ, Wang J, Gurumurthy CB, Bele A, Ellis IO, Green AR, Band H, Band V.

Breast Cancer Res Treat. 2013 Feb;137(3):721-31. doi: 10.1007/s10549-012-2363-3. Epub 2013 Jan 4.

2.

FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer.

Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO, Powe DG.

Breast Cancer Res Treat. 2011 Aug;129(1):11-21. doi: 10.1007/s10549-010-1161-z. Epub 2011 Feb 19.

PMID:
21336599
3.

Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer.

Alshareeda AT, Rakha EA, Nolan CC, Ellis IO, Green AR.

Breast Cancer Res Treat. 2012 Jul;134(2):519-29. doi: 10.1007/s10549-012-2083-8. Epub 2012 May 6.

PMID:
22562177
5.

Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.

Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V.

Clin Cancer Res. 2008 Aug 15;14(16):5228-35. doi: 10.1158/1078-0432.CCR-07-4528.

6.

Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.

Wang J, Li D, Wang B, Wu Y.

Breast Cancer Res Treat. 2013 Sep;141(2):213-24. doi: 10.1007/s10549-013-2679-7. Epub 2013 Sep 14.

PMID:
24036660
7.

Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma.

Grunewald TG, Kammerer U, Kapp M, Eck M, Dietl J, Butt E, Honig A.

BMC Cancer. 2007 Oct 23;7:198.

8.

Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM.

BMC Cancer. 2010 Nov 23;10:639. doi: 10.1186/1471-2407-10-639.

9.

Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer.

Chen X, Yun J, Fei F, Yi J, Tian R, Li S, Gan X.

Pathol Res Pract. 2012 Aug 15;208(8):437-43. doi: 10.1016/j.prp.2012.03.004. Epub 2012 Jun 8.

PMID:
22682760
10.

Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis.

Hadzisejdić I, Mustać E, Jonjić N, Petković M, Grahovac B.

Mod Pathol. 2010 Mar;23(3):392-403. doi: 10.1038/modpathol.2009.166. Epub 2010 Jan 8.

11.

Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.

Pellikainen J, Kataja V, Ropponen K, Kellokoski J, Pietiläinen T, Böhm J, Eskelinen M, Kosma VM.

Clin Cancer Res. 2002 Nov;8(11):3487-95.

12.

The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M.

Breast Cancer Res Treat. 2006 Jun;97(3):275-83. Epub 2005 Dec 13.

PMID:
16344916
13.

Expression of BRCA1 protein in breast cancer and its prognostic significance.

Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO.

Hum Pathol. 2008 Jun;39(6):857-65. doi: 10.1016/j.humpath.2007.10.011. Epub 2008 Apr 8.

PMID:
18400253
14.

DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.

Powe DG, Dhondalay GK, Lemetre C, Allen T, Habashy HO, Ellis IO, Rees R, Ball GR.

PLoS One. 2014 Jan 2;9(1):e84428. doi: 10.1371/journal.pone.0084428. eCollection 2014.

15.

A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers.

Frolova N, Edmonds MD, Bodenstine TM, Seitz R, Johnson MR, Feng R, Welch DR, Frost AR.

Tumour Biol. 2009;30(3):148-59. doi: 10.1159/000228908. Epub 2009 Jul 16. Erratum in: Tumour Biol. 2009;30(4):175.

16.

PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.

Takeshita T, Yamamoto-Ibusuki M, Yamamoto Y, Omoto Y, Honda Y, Iyama K, Zhang Z, Iwase H.

PLoS One. 2013 Nov 18;8(11):e80552. doi: 10.1371/journal.pone.0080552. eCollection 2013.

17.

Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.

Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, Shirouzu K, Kohno K, Yanagawa T, Yamana H, Nishio K, Ono M, Kuwano M, Kage M.

Cancer Res. 2008 Mar 1;68(5):1504-12. doi: 10.1158/0008-5472.CAN-07-2362.

18.

A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C.

J Pathol. 2012 Jan;226(1):97-107. doi: 10.1002/path.2976. Epub 2011 Sep 26.

PMID:
21953021
19.

P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.

Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los G, Rejto PA, Aparicio SA.

Mod Pathol. 2011 Jan;24(1):64-81. doi: 10.1038/modpathol.2010.189. Epub 2010 Sep 17.

20.

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R.

BMC Cancer. 2015 Jun 4;15:453. doi: 10.1186/s12885-015-1471-y.

Items per page

Supplemental Content

Write to the Help Desk